Table 4.
Most frequently reported adverse events for QPI-1002 versus placebo-treated patients Through day 30
Event | QPI-1002, n (%) | Placebo, n (%) |
---|---|---|
Hypotension | 5 (41.7) | 2 (50.0) |
Pleural effusion | 5 (41.7) | 1 (25.0) |
Anemia | 3 (25.0) | 2 (50.0) |
Constipation | 4 (33.3) | 0 (0.0) |
Nausea | 3 (25.0) | 0 (0.0) |
Leukocytosis | 3 (25.0) | 2 (50.0) |
Elevated AST | 3 (25.0) | 1 (25.0) |
Pulmonary edema | 3 (25.0) | 0 (0.0) |
Peripheral edema | 3 (25.0) | 0 (0.0) |
AST, aspartate transaminase.